Log In
Sign Up
Find a Lawyer
Ask a Lawyer
Research the Law
Law Schools
Laws & Regs
Newsletters
Marketing Solutions
Justia Connect
Pro Membership
Basic Membership
Justia Lawyer Directory
Platinum Placements
Gold Placements
Justia Elevate
SEO
Websites
Blogs
Justia Amplify
PPC Management
Google Business Profile
Social Media
Justia Onward Blog
Justia
Patents
Patents Assigned to DEUTSCHES KREBSFORSCHUNGSZENTRIUM
Patents Assigned to DEUTSCHES KREBSFORSCHUNGSZENTRIUM
18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
Patent number:
10016519
Abstract:
The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer.
Type:
Grant
Filed:
March 20, 2017
Date of Patent:
July 10, 2018
Assignees:
DEUTSCHES KREBSFORSCHUNGSZENTRIUM, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
Inventors:
Klaus Kopka, Martina Benesova, Jens Cardinale, Matthias Eder, Martin Schäfer, Ulrike Bauder-Wüst, Uwe Haberkorn, Michael Eisenhut